Stages IIIB-IV Lung Cancer – Non-Small Cell


Aetna Provides Coverage for Biodesix’ VeriStrat Test (06-25-2015)

Biodesix, Inc. announced that its VeriStrat® test is now considered a medically necessary benefit by Aetna Corporation (NYSE: AET).  Aetna published a positive coverage policy for the VeriStrat proteomic test on June 5th, stating the test is medically... Continue Reading

FDA Grants Breakthrough Therapy Designation for MPDL3280A, an anti-PDL1 Investigational Cancer Immunotherapy for Non-Small Cell Lung Cancer (02-26-2015)

The investigational cancer immunotherapy MPDL3280A (anti-PDL1) has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA). The designation was granted for the treatment of people with PD-L1 (Programmed Death-Ligand... Continue Reading

NFCR-Support Research Finds New Way to Combat Resistant Lung Cancer (02-11-2015)

A team of researchers at Massachusetts General Hospital has developed a new platform that can rapidly identify effective drug combinations for lung cancer patients whose tumors have stopped responding to targeted therapy. The research, which was supported... Continue Reading

Addition of Linifanib to Carboplatin-Paclitaxel Increases Progression-Free Survival and Toxicity in Advanced Nonsquamous NSCLC (02-10-2015)

In a phase II trial reported in the Journal of Clinical Oncology doctors reported that the addition of linifanib to carboplatin-paclitaxel chemotherapy the outcomes in patients with advanced nonsquamous non–small cell lung cancer (NSCLC). However the... Continue Reading

Stereotactic Body Radiation Therapy Improves Survival in Stage IV Non Small Cell Lung Cancer and Represents New Treatment Option (01-21-2015)

The results of a recent clinical trial published in the Journal of Clinical Oncology in patients with stage IV non small cell lung caner (NSCLC) suggest that combining stereotactic body radiation therapy (SBRT) with Tarceva (erlotinib) chemotherapy significantly... Continue Reading

FDA expands approved use of Cyramza to treat aggressive non-small cell lung cancer (01-8-2015)

The U.S. Food and Drug Administration today expanded the approved use of Cyramza (ramucirumab) to treat patients with metastatic non-small cell lung cancer (NSCLC). The most common type of lung cancer, NSCLC occurs when cancer cells form in the tissues... Continue Reading

Innovative Clinical Trials for Lung Cancer Currently Underway (01-7-2015)

The cancer research community is moving forward in its efforts find more effective treatment for patients with lung cancer. Current clinical trials are taking innovative approaches to how therapies for both advanced and early-stage lung cancers are studied.... Continue Reading

Dacomitinib Shows Activity in Selected Patients With Advanced Non-Small Cell Lung Cancer (12-9-2014)

In a phase II trial reported in The Lancet Oncology, doctors from Dana Farber Cancer Institute in Boston found that treatment of patients with advanced non–small cell lung cancer (NSCLC) with EGFR mutations or clinical characteristics associated with... Continue Reading

Xalkori™ (crizotinib) Targeted Therapy More Effective Than Chemotherapy for Treatment of Lung Cancer (12-6-2014)

A new drug Xalkori™ (crizotinib) is more beneficial than chemotherapy for certain individuals with lung cancer according to new research published in the New England Journal of Medicine. Lung cancer is the leading cause of cancer death in the U.S.... Continue Reading

Recent Treatment Advancements in Lung Cancer (12-5-2014)

By Christina S. Baik, MD, MPH Assistant Professor, University of Washington School of Medicine Assistant Member, Clinical Research Division, Fred Hutchinson Cancer Research Center Facing a lung cancer diagnosis? It is important to know the details of... Continue Reading

« Previous PageNext Page »